XML 43 R29.htm IDEA: XBRL DOCUMENT v3.7.0.1
Stock-Based Compensation (Details) - USD ($)
$ / shares in Units, $ in Millions
3 Months Ended
Mar. 31, 2017
Mar. 31, 2016
Stock Options/SARs and Employee Stock Purchase Plan (ESPP) Disclosures [Line Items]    
Common Shares Available for Grant 20,700,000  
Compensation expense related to the company's stock-based compensation plans $ 30.5 $ 32.4
Stock Options and SARs [Member]    
Stock Options/SARs and Employee Stock Purchase Plan (ESPP) Disclosures [Line Items]    
Unrecognized compensation expense $ 86.2  
Weighted average period over which unrecognized compensation expense will be recognized (in years) 2 years 7 months 6 days  
Stock-based compensation expense related to stock options, SAR and ESPP grants $ 11.0 $ 13.2
Weighted Average Fair Values And Valuation Assumptions Used To Value Stock Option/SARs, ESPP, and Performance Units/Stock Stock-Based Compensation [Abstract]    
Weighted Average Fair Value of Grants (price per share) $ 29.13 $ 20.87
Expected Volatility (in hundredths) 31.67% 36.45%
Risk-Free Interest Rate (in hundredths) 1.36% 1.03%
Dividend Yield (in hundredths) 0.67% 0.86%
Expected Life (in years) 5 years 3 months 18 days 5 years 3 months 18 days
Stock Options and SARs Rollforward [Abstract]    
Outstanding at January 1 (in shares) 9,850,000 10,744,000
Granted (in shares) 5,000 5,000
Exercised (1) (in shares) [1] (600,000) (258,000)
Forfeited (in shares) (99,000) (60,000)
Outstanding at March 31 (2) (in shares) [2] 9,156,000 10,431,000
Stock Options and SARs Vested or Expected to Vest (in shares) [3] 8,849,000 10,060,000
Stock Options and SARs Exercisable at March 31 (in shares) [4] 5,078,000 5,770,000
Weighted Average Grant Price Stock Option and SARs [Rollforward]    
Outstanding at January 1 (price per share) $ 75.53 $ 67.98
Granted (price per share) 101.61 69.03
Exercised (1) (price per share) [1] 57.53 43.44
Forfeited (price per share) 88.57 85.65
Outstanding at March 31 (2) (price per share) [2] 76.59 68.48
Weighted average grant price for stock options/SARs vested or expected to vest (price per share) [3] 76.20 68.04
Stock Options and SARs Exercisable at March 31 (price per share) [4] 67.74 58.68
ESPP [Member]    
Weighted Average Fair Values And Valuation Assumptions Used To Value Stock Option/SARs, ESPP, and Performance Units/Stock Stock-Based Compensation [Abstract]    
Weighted Average Fair Value of Grants (price per share) $ 24.28 $ 17.56
Expected Volatility (in hundredths) 30.33% 36.79%
Risk-Free Interest Rate (in hundredths) 0.65% 0.49%
Dividend Yield (in hundredths) 0.69% 0.82%
Expected Life (in years) 6 months 6 months
Restricted Stock And Restricted Stock Units [Member]    
Stock Options/SARs and Employee Stock Purchase Plan (ESPP) Disclosures [Line Items]    
Unrecognized compensation expense $ 168.5  
Weighted average period over which unrecognized compensation expense will be recognized (in years) 2 years 8 months 12 days  
Share-Based Compensation Arrangement By Restricted Stock And Restricted Stock Units Compensation Cost $ 18.6 $ 18.7
Restricted Stock/Restricted Stock Units and Performance Units/Performance Stock [Roll Forward]    
Outstanding at January 1 (in shares) 3,962,000 4,908,000
Granted (in shares) 402,000 284,000
Released (1) (in shares) [5] (360,000) (353,000)
Forfeited (in shares) (82,000) (39,000)
Outstanding at March 31 (2) (in shares) [6] 3,922,000 4,800,000
Weighted Average Grant Price Restricted Stock and Restricted Stock Units/Performance Units and Performance Stock [Roll Forward]    
Outstanding at January 1 (price per share) $ 79.63 $ 70.35
Granted (price per share) 99.52 75.26
Released (1) (price per share) [5] 61.96 53.88
Forfeited (price per share) 82.83 75.35
Outstanding at September 30 (2) (price per share) [6] $ 83.22 $ 71.81
Performance Units and Performance Stock [Member]    
Stock Options/SARs and Employee Stock Purchase Plan (ESPP) Disclosures [Line Items]    
Unrecognized compensation expense $ 9.6  
Weighted average period over which unrecognized compensation expense will be recognized (in years) 2 years 9 months 18 days  
Stock-based compensation expense related to stock options, SAR and ESPP grants $ 0.9 $ 0.5
Restricted Stock/Restricted Stock Units and Performance Units/Performance Stock [Roll Forward]    
Outstanding at January 1 (in shares) 545,290  
Granted (in shares) 118,834  
Released (1) (in shares) (89,224)  
Outstanding at March 31 (2) (in shares) 574,900  
Weighted Average Grant Price Restricted Stock and Restricted Stock Units/Performance Units and Performance Stock [Roll Forward]    
Aggregate intrinsic value of stock and units outstanding $ 56.1  
Intrinsic value of stock and units released during the year $ 9.0  
Performance Units and Performance Stock [Abstract]    
Minimum Performance Units and Stock Allowed to be Outstanding 299,540  
Maximum Performance Units and Stock Allowed to be Outstanding 850,260  
Maximum Vest Period from the Date of Grant 5 years  
Performance Period for Performance units and shares 3 years  
Minimum Performance Multiple at the Completion of the Performance Period 0.00%  
Maximum Performance Multiple at the Completion of the Performance Period 200.00%  
Lease And Well [Member]    
Stock Options/SARs and Employee Stock Purchase Plan (ESPP) Disclosures [Line Items]    
Compensation expense related to the company's stock-based compensation plans $ 10.9 10.4
Gathering And Processing Costs [Member]    
Stock Options/SARs and Employee Stock Purchase Plan (ESPP) Disclosures [Line Items]    
Compensation expense related to the company's stock-based compensation plans 0.2 0.3
Exploration Costs [Member]    
Stock Options/SARs and Employee Stock Purchase Plan (ESPP) Disclosures [Line Items]    
Compensation expense related to the company's stock-based compensation plans 6.2 6.5
General And Administrative [Member]    
Stock Options/SARs and Employee Stock Purchase Plan (ESPP) Disclosures [Line Items]    
Compensation expense related to the company's stock-based compensation plans $ 13.2 $ 15.2
[1] The total intrinsic value of stock options/SARs exercised for the three months ended March 31, 2017 and 2016 was $26.6 million and $7.3 million, respectively. The intrinsic value is based upon the difference between the market price of EOG's common stock on the date of exercise and the grant price of the stock options/SARs.
[2] The total intrinsic value of stock options/SARs outstanding at March 31, 2017 and 2016 was $199.3 million and $122.1 million, respectively. At March 31, 2017 and 2016, the weighted average remaining contractual life was 3.8 years and 3.9 years, respectively.
[3] The total intrinsic value of stock options/SARs vested or expected to vest at March 31, 2017 and 2016 was $196.0 million and $121.1 million, respectively. At March 31, 2017 and 2016, the weighted average remaining contractual life was 3.8 years and 3.9 years, respectively.
[4] The total intrinsic value of stock options/SARs exercisable at March 31, 2017 and 2016 was $155.5 million and $108.7 million, respectively. At March 31, 2017 and 2016, the weighted average remaining contractual life was 2.4 years and 2.7 years, respectively.
[5] The total intrinsic value of restricted stock and restricted stock units released for the three months ended March 31, 2017 and 2016 was $36.0 million and $24.7 million, respectively. The intrinsic value is based upon the closing price of EOG's common stock on the date the restricted stock and restricted stock units are released.
[6] The total intrinsic value of restricted stock and restricted stock units outstanding at March 31, 2017 and 2016 was $382.6 million and $348.4 million, respectively.